MXPA04009929A - Tratamiento de la gastroparesis. - Google Patents

Tratamiento de la gastroparesis.

Info

Publication number
MXPA04009929A
MXPA04009929A MXPA04009929A MXPA04009929A MXPA04009929A MX PA04009929 A MXPA04009929 A MX PA04009929A MX PA04009929 A MXPA04009929 A MX PA04009929A MX PA04009929 A MXPA04009929 A MX PA04009929A MX PA04009929 A MXPA04009929 A MX PA04009929A
Authority
MX
Mexico
Prior art keywords
gastroparesis
treatment
glp
patients
compounds
Prior art date
Application number
MXPA04009929A
Other languages
English (en)
Spanish (es)
Inventor
Thurman Dwight Mckinney
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA04009929A publication Critical patent/MXPA04009929A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MXPA04009929A 2002-04-10 2003-03-27 Tratamiento de la gastroparesis. MXPA04009929A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10
PCT/US2003/008457 WO2003087139A2 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis

Publications (1)

Publication Number Publication Date
MXPA04009929A true MXPA04009929A (es) 2006-03-10

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04009929A MXPA04009929A (es) 2002-04-10 2003-03-27 Tratamiento de la gastroparesis.

Country Status (18)

Country Link
US (1) US20050164925A1 (enExample)
EP (1) EP1496924A4 (enExample)
JP (1) JP2005530732A (enExample)
KR (1) KR20040098063A (enExample)
CN (1) CN1735423A (enExample)
AU (1) AU2003220403A1 (enExample)
BR (1) BR0308904A (enExample)
CA (1) CA2480858A1 (enExample)
EA (1) EA200401345A1 (enExample)
EC (1) ECSP045345A (enExample)
HR (1) HRP20040939A2 (enExample)
IL (1) IL164266A0 (enExample)
MX (1) MXPA04009929A (enExample)
NO (1) NO20044815L (enExample)
NZ (1) NZ535684A (enExample)
PL (1) PL373658A1 (enExample)
WO (1) WO2003087139A2 (enExample)
ZA (1) ZA200408111B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
JP4960700B2 (ja) 2003-07-21 2012-06-27 メタキュアー リミティド 疾患を治療し、血糖を制御する際に使用するための胃腸処置方法および装置
EP1670515A2 (en) * 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
TW200522976A (en) * 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
EP1793891B1 (en) 2004-08-18 2011-11-09 Metacure Limited Monitoring, analysis, and regulation of eating habits
EP1868679B1 (en) 2005-02-17 2017-05-03 MetaCure Limited Non-immediate effects of therapy
EP1880298B1 (en) 2005-02-17 2016-07-13 Metacure Limited Charger with data transfer capabilities
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
ES2484796T3 (es) 2005-03-18 2014-08-12 Novo Nordisk A/S Compuestos de GLP-1 extendidos
US8463404B2 (en) 2005-03-24 2013-06-11 Metacure Limited Electrode assemblies, tools, and methods for gastric wall implantation
ATE533403T1 (de) * 2005-03-24 2011-12-15 Metacure Ltd Drahtlose leitungen für magen-darm-trakt- anwendungen
US8301256B2 (en) 2005-06-02 2012-10-30 Metacure Limited GI lead implantation
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
EP2007804B1 (en) * 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
WO2008139463A2 (en) * 2007-05-09 2008-11-20 Metacure Ltd. Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
WO2010015668A1 (en) 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
EP2482840A4 (en) * 2009-08-07 2013-06-26 Mannkind Corp VAL (8) GLP-1 COMPOSITION AND METHOD FOR THE TREATMENT OF REAGENTS AND / OR IRRITATION SYNDROME
PL2525834T3 (pl) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Hormony wzrostu o przedłużonej skuteczności in-vivo
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
PH12012502018A1 (en) 2010-04-30 2018-03-21 Sanwa Kagaku Kenkyusho Co Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
ES2841123T3 (es) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Formulación del compuesto de la hormona de crecimiento

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
AU2003220403A1 (en) 2003-10-27
PL373658A1 (en) 2005-09-05
HRP20040939A2 (en) 2004-12-31
JP2005530732A (ja) 2005-10-13
EP1496924A4 (en) 2007-05-30
CA2480858A1 (en) 2003-10-23
US20050164925A1 (en) 2005-07-28
ZA200408111B (en) 2005-10-07
IL164266A0 (en) 2005-12-18
NO20044815L (no) 2005-01-07
NZ535684A (en) 2006-03-31
BR0308904A (pt) 2005-05-03
EA200401345A1 (ru) 2005-08-25
EP1496924A2 (en) 2005-01-19
WO2003087139A3 (en) 2004-01-08
CN1735423A (zh) 2006-02-15
ECSP045345A (es) 2006-04-19
KR20040098063A (ko) 2004-11-18
WO2003087139A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
WO2003087139A3 (en) Treatment of gastroparesis
MY137757A (en) Therapeutic treatment
AU2003300791A1 (en) Combination therapy for the treatment of pain
GB0201850D0 (en) Therapeutic treatment
WO2006113802A3 (en) Device for administering electrode stimulation of back and abdominal muscles
GB0216321D0 (en) Therapeutic treatment
EP1572095A4 (en) S-L-2 DESOXYNUCLEOSIDE FOR THE TREATMENT OF RESISTANT HBV-STRAINS AND COMBINATION THERAPIES
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
MXPA04004306A (es) Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
GB0223367D0 (en) Therapeutic treatment
PL363679A1 (en) Novel use of 2-phenyl-substituted imidazotriazinones
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
GB0223854D0 (en) Therapeutic treatment
PT1670489E (pt) Utilização de xénon com hipotermia para o tratamento de asfixia neonatal
SI1603584T1 (sl) Aplidin za zdravljenje multiple mieloma
LT1496918T (lt) Natrio meta-arsenito naudojimas navikams gydyti
PL375629A1 (en) 1-phenyl-2-dimethylaminomethyl cyclohexane compounds used for the therapy of depressive symptoms, pain, and incontinence
GB0210464D0 (en) Therapeutic treatment
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
MXPA03006742A (es) Uso de buprenorfina para la terapia de la incontinencia urinaria.
IL164951A0 (en) The treatment of pain with lfendropil
MXPA05012605A (es) Composiciones que comprenden compuestos de gastrina y sus usos en la diabetes.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal